Role of KRAS-LCS6 Polymorphism in Advanced NSCLC Patients Treated With Erlotinib or Docetaxel in Second Line Treatment (TAILOR)

Scientific Reports - United Kingdom
doi 10.1038/srep16331
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

P1.01-93 Quality of Life in Patients With Advanced NSCLC Treated in Second- Or Third-Line With Nab-Paclitaxel + Durvalumab: ABOUND.2L+

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.13-11 Advanced NSCLC Treated With Gefitinib or Erlotinib for Five Years or Longer - Retrospective Slovakian Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-110 Defining Aggressive Disease in Patients With Advanced NSCLC Receiving Second-Line Treatment: A Systematic Review

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

KRAS Mutation, KRAS–LCS6 Polymorphism, and Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2010English

P3.01-86 Treatment Outcomes With Reduced Frequency of Nivolumab Dosing as Second-Line Therapy in Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Korean Journal of Internal Medicine
Internal Medicine
2007English

P1.01-70 Efficacy and Safety of Second- Or Third-Line Nab-Paclitaxel + Durvalumab in Patients With Advanced NSCLC (ABOUND.2L+)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Docetaxel as Second Line After Failure of Gemcitabine/Cisplatin Regimen in Advanced and/or Metastatic Urinary Bladder Cancer Patients in Egypt

Research in Oncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy